BIOMAT Database Logo BIOMAT Database Logo

Cyclic enaminone as new chemotype for selective cyclooxygenase-2 inhibitory, anti-inflammatory, and analgesic activities. 2019

Raj Kumar, and Nirjhar Saha, and Priyank Purohit, and Sanjeev K Garg, and Kapileswar Seth, and Vachan S Meena, and Sachin Dubey, and Khyati Dave, and Rohit Goyal, and Shyam S Sharma, and Uttam C Banerjee, and Asit K Chakraborti
Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, 160 062, Punjab, India.

The cyclic enaminone moiety has been identified as a new scaffold for selective inhibition of cyclooxygenase-2 with anti-inflammatory and analgesic activities. The designed cyclic enaminones have been synthesized conveniently through the development of a new catalyst-free methodology and evaluated for cyclooxygenase (COX-1 and COX-2) inhibitory activities. Three compounds 7d, 8, and 9 predominantly inhibited COX-2 with selectivity index of 74.09, 19.45 and 108.68, respectively, and were assessed for in vivo anti-inflammatory activity in carrageenan induced rat paw edema assay. The anti-inflammatory activity of 7d was comparable to that of celecoxib at a dose of 12.5 mg/kg. However, the compounds 8 and 9 were more/equally effective as anti-inflammatory agent compared to celecoxib at the doses of 12.5 mg/kg and 25 mg/kg and also exhibited anti-inflammatory activity comparable to that of diclofenac. The therapeutic potential of the most active compound 9 was further assessed by performing in vivo thermal and mechanical hyperalgesia tests using various models that revealed its analgesic activity. The in vivo non-ulcerogenicity of 9 revealed the gastrointestinal safety as compared to the non-selective COX inhibitor indomethacin. The in vitro antioxidant activity and in vivo experiments on heart rate and blood pressure provided the cardiovascular safety profile of 9. The molecular docking studies rationalize the COX-2 selectivity of the newly found anti-inflammatory compounds 7d, 8, and 9.

UI MeSH Term Description Entries
D008297 Male Males
D002351 Carrageenan A water-soluble extractive mixture of sulfated polysaccharides from RED ALGAE. Chief sources are the Irish moss CHONDRUS CRISPUS (Carrageen), and Gigartina stellata. It is used as a stabilizer, for suspending COCOA in chocolate manufacture, and to clarify BEVERAGES. Carrageenin,iota-Carrageenan,kappa-Carrageenan,lambda-Carrageenan,iota Carrageenan,kappa Carrageenan,lambda Carrageenan
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004487 Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE. Dropsy,Hydrops,Anasarca
D006571 Heterocyclic Compounds Cyclic compounds that include atoms other than carbon in their ring structure. Heterocyclic Compound,Compound, Heterocyclic,Compounds, Heterocyclic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000700 Analgesics Compounds capable of relieving pain without the loss of CONSCIOUSNESS. Analgesic,Anodynes,Antinociceptive Agents,Analgesic Agents,Analgesic Drugs,Agents, Analgesic,Agents, Antinociceptive,Drugs, Analgesic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous

Related Publications

Raj Kumar, and Nirjhar Saha, and Priyank Purohit, and Sanjeev K Garg, and Kapileswar Seth, and Vachan S Meena, and Sachin Dubey, and Khyati Dave, and Rohit Goyal, and Shyam S Sharma, and Uttam C Banerjee, and Asit K Chakraborti
Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities.
March 2015, European journal of medicinal chemistry,
Raj Kumar, and Nirjhar Saha, and Priyank Purohit, and Sanjeev K Garg, and Kapileswar Seth, and Vachan S Meena, and Sachin Dubey, and Khyati Dave, and Rohit Goyal, and Shyam S Sharma, and Uttam C Banerjee, and Asit K Chakraborti
Exploring of novel oxazolones and imidazolones as anti-inflammatory and analgesic candidates with cyclooxygenase inhibitory action.
April 2024, Future medicinal chemistry,
Raj Kumar, and Nirjhar Saha, and Priyank Purohit, and Sanjeev K Garg, and Kapileswar Seth, and Vachan S Meena, and Sachin Dubey, and Khyati Dave, and Rohit Goyal, and Shyam S Sharma, and Uttam C Banerjee, and Asit K Chakraborti
Comparison of analgesic and anti-inflammatory efficacy of selective and non-selective cyclooxygenase-2 inhibitors in dental implant surgery.
December 2007, Journal of periodontology,
Raj Kumar, and Nirjhar Saha, and Priyank Purohit, and Sanjeev K Garg, and Kapileswar Seth, and Vachan S Meena, and Sachin Dubey, and Khyati Dave, and Rohit Goyal, and Shyam S Sharma, and Uttam C Banerjee, and Asit K Chakraborti
Investigations of new pyridazinone derivatives for the synthesis of potent analgesic and anti-inflammatory compounds with cyclooxygenase inhibitory activity.
September 2003, Archiv der Pharmazie,
Raj Kumar, and Nirjhar Saha, and Priyank Purohit, and Sanjeev K Garg, and Kapileswar Seth, and Vachan S Meena, and Sachin Dubey, and Khyati Dave, and Rohit Goyal, and Shyam S Sharma, and Uttam C Banerjee, and Asit K Chakraborti
[New nonsteroidal anti-inflammatory agents: nitric oxide donors and selective cyclooxygenase-2 inhibitors].
August 1999, La Revue de medecine interne,
Raj Kumar, and Nirjhar Saha, and Priyank Purohit, and Sanjeev K Garg, and Kapileswar Seth, and Vachan S Meena, and Sachin Dubey, and Khyati Dave, and Rohit Goyal, and Shyam S Sharma, and Uttam C Banerjee, and Asit K Chakraborti
Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents.
August 1998, Current opinion in chemical biology,
Raj Kumar, and Nirjhar Saha, and Priyank Purohit, and Sanjeev K Garg, and Kapileswar Seth, and Vachan S Meena, and Sachin Dubey, and Khyati Dave, and Rohit Goyal, and Shyam S Sharma, and Uttam C Banerjee, and Asit K Chakraborti
Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
April 1996, Journal of medicinal chemistry,
Raj Kumar, and Nirjhar Saha, and Priyank Purohit, and Sanjeev K Garg, and Kapileswar Seth, and Vachan S Meena, and Sachin Dubey, and Khyati Dave, and Rohit Goyal, and Shyam S Sharma, and Uttam C Banerjee, and Asit K Chakraborti
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
October 1995, Journal of medicinal chemistry,
Raj Kumar, and Nirjhar Saha, and Priyank Purohit, and Sanjeev K Garg, and Kapileswar Seth, and Vachan S Meena, and Sachin Dubey, and Khyati Dave, and Rohit Goyal, and Shyam S Sharma, and Uttam C Banerjee, and Asit K Chakraborti
[Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
November 2000, La Revue de medecine interne,
Raj Kumar, and Nirjhar Saha, and Priyank Purohit, and Sanjeev K Garg, and Kapileswar Seth, and Vachan S Meena, and Sachin Dubey, and Khyati Dave, and Rohit Goyal, and Shyam S Sharma, and Uttam C Banerjee, and Asit K Chakraborti
Synthesis, Anti-Inflammatory and Anti- Nociceptive Activities and Cytotoxic Effect of Novel Thiazolidin-4-ones Derivatives as Selective Cyclooxygenase (COX-2) Inhibitors.
December 2013, Iranian journal of basic medical sciences,
Copied contents to your clipboard!